DPP4 and type 2 diabetes mellitus: The interest raised by this molecule is linked to the approval of DPP-4 inhibitors for T2D treatment (gliptins as vildagliptin, saxagliptin, alogliptin, sitagliptin, and linagliptin), as monotherapy or as an adjunctive agent with other drugs, with numerous advantages with respect to traditional treatments [53].